Kailera Therapeutics, Inc. (KLRA) Stock

NASDAQ: KLRAHealthcare company in the biotechnology industry, based in Waltham, MA.

Kailera Therapeutics stock price chart

KLRA interactive chart →

KLRA stock quote & key statistics

Kailera Therapeutics earnings per share

Income →
Earnings per share

Kailera Therapeutics revenue & net income

Income →
RevenueNet income

Kailera Therapeutics annual financials

Income statement →
Fiscal yearRevenueNet incomeEPS
FY2025$0-$149.0M—

Fiscal year ending December 31. Source: company filings via EODHD.

About Kailera Therapeutics, Inc.

Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist.

Kailera Therapeutics holds exclusive rights for global development and commercialization of four metabolic disease assets outside of Greater China, with therapies delivered through oral and injectable formulations. The company was founded in 2024 and is based in Waltham, Massachusetts.

Kailera Therapeutics stock FAQ

What is the Kailera Therapeutics stock ticker symbol?

Kailera Therapeutics, Inc. trades on the NASDAQ under the ticker symbol KLRA.

What sector and industry is Kailera Therapeutics in?

Kailera Therapeutics, Inc. is classified in the Healthcare sector, Biotechnology industry.

How many employees does Kailera Therapeutics have?

Kailera Therapeutics, Inc. has about 145 full-time employees.

What were Kailera Therapeutics's revenue and earnings last fiscal year?

Kailera Therapeutics reported revenue of $0 and net income of -$149.0M in fiscal 2025.

Is Kailera Therapeutics in the Russell 2000?

Yes. Kailera Therapeutics, Inc. (KLRA) is a component of the Russell 2000, the benchmark index of U.S. small-cap stocks.

When did Kailera Therapeutics go public?

Kailera Therapeutics stock began trading on April 17, 2026.

Russell 2000 Biotechnology stocks

All Russell 2000 →